The classic website will no longer be available as of June 25, 2024. Please use the modernized
Working… Menu

A US Study to Evaluate Transarterial Radioembolization (TARE) in Combination With Durvalumab and Bevacizumab Therapy in People With Unresectable Hepatocellular Carcinoma Amenable to TARE (EMERALD-Y90)

The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Know the risks and potential benefits of clinical studies and talk to your health care provider before participating. Read our disclaimer for details. Identifier: NCT06040099
Recruitment Status : Recruiting
First Posted : September 15, 2023
Last Update Posted : May 29, 2024
Information provided by (Responsible Party):

No Study Results Posted on for this Study
Recruitment Status : Recruiting
Estimated Primary Completion Date : July 23, 2026
Estimated Study Completion Date : July 23, 2026